Wednesday, August 10, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

NIH: Vaccines Protect Monkeys Against Zika Infection

by Global Biodefense Staff
August 25, 2016
Biodefense Vaccine Development

Credit: Shutterstock, modified by Global Biodefense

The National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) is supporting research and development of multiple Zika vaccine candidates.

Dr. Dan H. Barouch leads a research team at Harvard Medical School and Beth Israel Deaconess Medical Center that is collaborating with scientists at Walter Reed Army Institute of Research and the University of São Paulo. They previously showed progress developing Zika vaccines in mice. In their latest study, they tested 3 different vaccine approaches in rhesus macaques, an important animal model. Results appeared online on August 4, 2016, in Science.

The researchers first tested an inactivated Zika virus vaccine in 16 rhesus macaques. Half the animals received the experimental vaccine and half a placebo injection. Within 2 weeks after the initial injection, all vaccinated animals developed antibodies to the Zika virus. A second dose given 4 weeks later substantially boosted antibody levels.

When the monkeys were exposed to Zika virus, the group that received the placebo injections developed high levels of virus in blood and other tissues for 6 to 7 days. Vaccinated animals had no detectable virus and showed no other evidence of infection.

In another experiment, the team tested 2 vaccines designed to trigger an immune response against the viral envelope protein, a key vaccine target on the Zika virus. The scientists administered 2 doses of an experimental DNA vaccine, 1 dose of an experimental adenovirus vector vaccine, or a placebo injection to 3 groups of 4 monkeys each. The group that received the DNA vaccine received a booster shot 4 weeks later.

The researchers detected significant Zika-neutralizing antibodies in the animals after the second DNA vaccine injection. The adenovirus vector-based vaccine induced Zika-specific neutralizing antibodies 2 weeks after the single injection.

The monkeys were exposed to Zika virus 4 weeks after the final vaccinations. Both the DNA and adenovirus vector vaccines provided complete protection against infection. None of the vaccines produced adverse side effects.

“Three vaccines provided complete protection against Zika virus in nonhuman primates, which is the best animal model prior to starting clinical trials,” Barouch says. “The consistent and robust protection against Zika virus in both rodents and primates fuels our optimism about the development of a safe and effective Zika vaccine for humans.”

Read more: Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys.

Tags: Emerging ThreatsVaccinesWRAIRZika

Related Posts

Influenza Transmission Spikes During Social Gatherings
Medical Countermeasures

New Universal Flu Vaccine Offers Broad Protection Against Influenza A Virus Infections

July 17, 2022
Adverse Events After Simultaneous COVID-19 mRNA Booster, Flu Vaccination
Medical Countermeasures

Adverse Events After Simultaneous COVID-19 mRNA Booster, Flu Vaccination

July 16, 2022
US Starts Clinical Trial for mRNA Nipah Virus Vaccine
Medical Countermeasures

US Starts Clinical Trial for mRNA Nipah Virus Vaccine

July 11, 2022
Targeting Poxviruses with Messenger RNA Technology
Medical Countermeasures

Targeting Poxviruses with Messenger RNA Technology

July 11, 2022
Load More

Latest News

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

July 27, 2022
Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

July 17, 2022
Influenza Transmission Spikes During Social Gatherings

New Universal Flu Vaccine Offers Broad Protection Against Influenza A Virus Infections

July 17, 2022
Long COVID: National Academies’ Panel Examines Long-Term Health Effects of COVID-19

Long COVID: National Academies’ Panel Examines Long-Term Health Effects of COVID-19

July 17, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC